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mg od; amiloride 10mg od and chlorthalidone 25mg od), 4-period crossover, lasting 32 weeks. Equal numbers
of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the
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Conclusion: AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate ﬁrst- and
second-line antihypertensive therapies for multiethnic populations.© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Table I
Trial objectives
Primary objective
- To determine whether the response to antihypertensive drugs differs on the
basis of SDE
Secondary objectives
- To determine if the response to antihypertensive drugs differs by:
- AIMs
- Baseline metabolomics
- Baseline hemodynamics
- Genomics
- Detailed SDE (family tree extending to grandparents)
- To compare detailed SDE with AIMs as a cause for the response to
antihypertensive drugs
- To determine the most effective mono- and dual therapy for hypertension and
whether this varies by ethnicity
- To determine whether metabolomics and hemodynamics differ by ethnicity
- To test whether previously identiﬁed biomarkers (derived from other cohorts,
eg, United States) can predict drug responseHypertension is the single biggest contributor to the global burden
of disease, a burden that is particularly great in lower- and middle-
income countries.1 In high-income economies, ethnic minorities—
often originating from lower- and middle-income countries—also
appear to be disproportionately affected when compared to indige-
nous populations.2-4 Complex interactions between genes and the en-
vironment are thought to inﬂuence the pathophysiology of essential
hypertension, the frequency of hypertension-related complications,
and the response to treatment.1 However, data relating to ethnicity
are complicated by the plethora of methods used to deﬁne ethnicity
or race, and a greater understanding of environmental inﬂuences has
led to the recognition that data collected in one country may not be
readily applicable to similar ethnic groups in distinct geographical
locations.1
European guidelines relating to themanagement of arterial hyper-
tension make no allowance for ethnicity.5 In contrast, the North
American guideline, published by the Joint National Committee in
2014, does, stating, “In the general black population, including those
with diabetes, initial antihypertensive treatment should include a
thiazide-type diuretic or CCB [calcium channel blocker].”6 Stratiﬁed
by age and self-deﬁned ethnicity (SDE), the UK's National Institute
for Health and Care Excellence (NICE) recommends a third approach,
with distinct initial monotherapies recommended for all those aged
55 years and over, as well as for younger black adults when compared
towhites.7 However, the guidelinemakes no reference to South Asians
(ie, those originating from the Indian subcontinent)—despite the fact
that they represent the largest ethnic minority group in the United
Kingdom at 4.7 million people (52.5 million “white British” citizens
being the largest group within a total population of 65.6 million
people).7,8 Furthermore, the aforementioned guidelines fail to extend
stratiﬁcation to combination therapy.5-7
Stratiﬁcation on the basis of SDE is potentially ﬂawed by virtue of an
increasingly “admixed” population, the complex relationship between
ethnicity and phenotype, and its inherent cohort-based approach
which fails to account for interindividual variations.9 An alternative
method of stratiﬁcation seeks to use ancestry informative markers
(AIMs)—genetic polymorphisms occurring with substantially different
frequencies across populations from distinct geographical regions. Able
to predict geographical ancestry, AIMs may capture the genetic compo-
nent responsible for variations in drug response among ethnically di-
verse populations more discerningly than SDE.9,10 Concurrent
metabolomic proﬁling of plasma and urine (measurement of low– and
intermediate–molecular weight metabolites which reﬂect the complex
interplay between genetic, physiological, pathophysiological, and/or en-
vironmental factors) offers the potential to augment AIMs, with differ-
ences between individuals reﬂecting the entire spectrum of inﬂuences,
especially diet.11,12
In an effort to address these issues, the AIM-HY INFORM trial in-
tends to compare variations in response to antihypertensive agents
among 3 cohorts of the UK population stratiﬁed on the basis of SDE,
while also relating any variations to AIMs and metabolomic proﬁles.
In doing so, we hope to evaluate the validity of current NICE guidance
whichhas SDE at the center of its approach to pharmacotherapy and to
examine whether use of AIMs and/or metabolomic proﬁling results inthemore effective personalization of antihypertensive treatment. Fur-
thermore, the trial will evaluate the efﬁcacy of bothmonotherapy and
dual therapy across all 3 cohorts and try to elucidate potential mecha-
nisms underlying any difference in outcomes achieved by using SDE
and AIMs. Thus, AIM-HY INFORM will enable clinicians to optimize
their choice of antihypertensive treatments from current, generic,
ﬁrst- and second-line agents, reducing the attrition of antihyperten-
sive therapies.
Hypotheses
Wehypothesize that the response to antihypertensive drugs (used
either as mono- or dual therapy) differs by ethnicity.
Our secondary hypothesis relates to the possibility that AIMs and
metabolites, and/or baseline hemodynamic measurements, are able
to predict response to antihypertensive therapy.
Methods
Study design and objectives
AIM-HY INFORM is a multicenter, prospective, open-label study
with 2 parallel, independent trial arms (mono- and dual therapy).
Eleven UK sites will enroll a total of 1,320 patients. Those receiving
monotherapy (n= 660) will enter a 3-treatment, 3-period crossover,
lasting 24weeks, whereas those receiving dual therapy (n=660)will
enter a 4-treatment, 4-period crossover, lasting 32weeks. Equal num-
bers of all 3 ethnic groups (white, black/black British, and Asian/Asian
British) will ultimately be recruited to each of the trial arms (ie, 220
participants per ethnic group per arm).
The primary objective of the AIM-HY INFORM trial is to determine
whether the response to antihypertensive drugs differs on the basis of
SDE. Secondary objectives (Table I) include an evaluation of this
Table II
Selection criteria
Inclusion criteria
1. Able to give written informed consent
2. Aged 18 to 65 y
3. SDE falling into 1 of 3 groups:
- White (white British, white Irish, or any other white background)
- Black/black British (black Caribbean, black African, or any other black background)
- Asian/Asian British (Asian Indian, Asian Pakistani, Asian Bangladeshi, or any other South Asian
background)
4. Hypertensive as deﬁned by:
-Monotherapy
- Treatment-naive patients:
Daytime average SBP ≥135 mm Hg or DBP ≥85 mm Hg
Using ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) (validated device based on an average of 10 readings)
- Treated patients:
Daytime average SBP ≥135 mm Hg or DBP ≥85 mm Hg
Using ABPM or HBPM (validated device based on an average of 10 readings), if:
Likely to achieve control on a study drug while being willing and able to complete 2-4 wk washout
- Dual therapy
- Treated (with 1–3 antihypertensive agents):
Daytime average SBP 135-200 mm Hg and/or DBP 85-110 mm Hg
Using ABPM or HBPM (validated device based on an average of 10 readings)
Exclusion criteria
a. Inability to identify with one of the predeﬁned ethnic groups, eg, admixed origin
b. Pregnant or breastfeeding women
c. Known or suspected secondary hypertension
d. Signiﬁcant sensitivity or contraindications to study medicines
e. Concomitant lithium or variable-dose non-steroidal anti-inﬂammatory drugs (NSAID) use
f. A requirement to take any of the study drugs continuously, eg, ACEi and heart failure
g. Clinically signiﬁcant hepatic impairment
h. Clinically signiﬁcant kidney impairment
i. Concurrent clinical trial participation (systemically vasoactive medicines or drugs known to interact with the study medicines)
j. Patients deemed unsuitable by the investigator on clinical grounds, eg, patients in atrial ﬁbrillation
SDE: self deﬁned ethnicity; SBP: systolic blood pressure; DBP: diastolic blood pressure; NSAID: non-steroidal anti-inﬂammatory drugs; ACEi: angiotensin converting enzyme inhibitors.
a b
YES
YES
YES
YES
YES NO
NO
AIM HY INFORM Clinical Trial 
Approx. 1320 patients 
MONO-THERAPY STUDY 
Approx. 660 patients (220 per ethnic group)
DUAL-THERAPY STUDY 
Approx. 660 patients (220 per ethnic group)
Newly diagnosed hypertensive 
APBM ≥ 135/85 mmHg
On NO hypertensive medication
Patients taking hypertensive 
medication who are suitable 
and willing to washout
Established Hypertension 
on 1-3 hypertensive medications 
AND BP ≥135/85 and/or ≤200/110 mmHg
Patient can be washed out
(Office BP <160/100 mmHg)
Minimum 2 week washout
Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^ Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^
Randomisation (open label) – Monotherapy rotation
Ensure consented to Dual-Therapy 
A - Amlodipine
C - Chlortalidone B - Lisinopril
5 mg 
10 mg 
Wk 1 2 8
Amlodipine
10 mg 
20 mg 
Wk 1 2 8
Lisinopril
25 mg 
8 weeks
Wk 1 8
Chlortalidone
8 weeks
8 weeks
8 weeks8 weeks
8 weeks
A - Amlodipine
B - Lisinopril
20 mg + 25 mg 
Wk 1 8
5 mg + 20 mg 
Wk
1 8
5 mg + 25 mg 
Wk
1 8
A - Amlodipine
C - Chlortalidone
C - Chlortalidone
25 mg + 10 mg 
Wk 1 8
D - Amiloride
B - Lisinopril
C - Chlortalidone 8 weeks
*OMICS = Metabolomic and Genomic analysis
** Dose up-titration in 1 or 2 weeks
^ CRF = Clinical Research Facility
Completed Mono-Therapy but fails 
to achieve target (<135/85 mmHg) –
may be eligible for Dual-Therapy
Ensure consented to Mono-Therapy
** 
**
Randomisation (open label) – Dual therapy rotation
Figure. Trial ﬂowchart.
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dynamic data, genomics, and amore detailed evaluationof SDE (with a
family tree extending to 3 generations, ie, grandparents). Additionally,
the trial aims to determine (1) the most effective mono- and dualtherapy for hypertension and any variation(s) by ethnicity, (2)
whether metabolomics and hemodynamics differ by ethnicity, and
(3) whether previously identiﬁed biomarkers (ie, those derived from
other cohorts, eg, the United States) can predict the therapeutic
Table III
Selection criteria
Monotherapy
A. 1-2 wk of amlodipine 5 mg od followed by 6-7 wk of amlodipine 10 mg od
B. 1-2 wk of lisinopril 10 mg od followed by 6-7 weeks of lisinopril 20 mg od
C. Approximately 8 wk of chlorthalidone 25 mg od
Dual therapy
A. Approximately 8 wk of amlodipine 5 mg od and lisinopril 20 mg od
B. Approximately 8 wk of amlodipine 5 mg od and chlorthalidone 25 mg od
C. Approximately 8 wk of lisinopril 20 mg od and chlorthalidone 25 mg od
D. Approximately 8 wk of amiloride 10 mg od and chlorthalidone 25 mg od
Table IV
Outcome measures
Primary outcome measure
- Seated, automated, unattended, ofﬁce SBP, measured approximately 8 wk after
each treatment
Secondary outcome measures
- All participants
- Seated, automated, ofﬁce DBP
- Detailed SDE
- Core cardiovascular measurements
- Body composition assessment to determine lean and fat tissue mass
- Pulse wave analysis (carotid & femoral arteries) to derive pulse wave
velocity, central (aortic) waveforms, and central BP
- Echocardiography (including left ventricular mass and volume
assessments)
- Dundee (3-min) step test (baseline only)
- Subgroups
- ABPM and/or HBPM
- Optional cardiovascular measurements
- Heart rate variability
- Regional arterial diameters
- cardiac output (CO) and stroke volume (SV) assessment (using a
noninvasive, inert gas rebreathing technique)
Tertiary outcome measures
- Hemodynamic and genomic measures
- Baseline demographics comparison
- Urine drug screening (random subgroup sample)
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deﬁned.
Study population, treatment assignment, and randomization
The inclusion and exclusion criteria are listed in Table II. Hyperten-
sive adults aged between 18 and 65 years are eligible for inclusion pro-
vided that they are able to self-identify with 1 of the 3 ethnicities
outlined. Treatment-naive individuals will be conﬁned to the mono-
therapy arm. Those who have previously been treated/are being
treated with antihypertensive agents will be able to enter either arm
provided that they are able to undergo a washout of 2-4 weeks; if
not, they will be assigned to dual therapy.
Following allocation to a trial arm, subjects will be randomized to a
sequence of drugs (Figure) using an online system (https://www.
sealedenvelope.com). This requires the participant screening number,
initials, date of birth, and SDE, along with the site name, conﬁrmation
of eligibility, and trial arm allocation. For those receiving monotherapy,
6 possible treatment sequences may be generated, as the intervention
consists of a 3-treatment, 3-period crossover: ABC, ACB, BAC, BCA,
CAB, and CBA. Where subjects are allocated dual therapy (a 4-
treatment, 4-period crossover), 4 possible treatment sequences
exist: ABDC, BCAD, CDBA, and DACB. In both instances, a Latin square
balanced for ﬁrst-order carryover effects is deployed13; the randomi-
zation schedule will also aim to have equal numbers of participants
in each sequence.
Prescribed in an open-labelmanner, the treatments allocated to each
letter are detailed in Table III. Stable concomitant therapy for unrelated
indications is permitted provided that it does not have an antihyperten-
sive effect; dose modiﬁcations for the trial drugs are not permitted. As
this is a pragmatic trial of licensed medications, overall adherence will
be assessed by urine drug screening for the study medications in a ran-
domly selected subgroup of individuals (n = 50). Participants will also
be asked to self-report on compliance; where this falls below 75%, sub-
jects may be withdrawn at the discretion of the principal/chief investi-
gator(s).
Outcome measures
The primary outcomemeasure is seated, ofﬁce, unattended systolic
blood pressure (SBP) measured 8 weeks after each treatment period
begins. A validated, automated, brachial BP machine—the Omron
HEM-907—will be used to record 3 serial measurements.
Secondary and tertiary outcome measures are shown in Table IV.
Analysis of potential genetic polymorphisms associated with response
to antihypertensive treatmentwill be limited to those polymorphisms
previously linked to BP via genome-wide association studies.14 Prelim-
inary retrospective analyses of randomized controlled trials evaluating
the efﬁcacy of antihypertensive drugs suggest that many of these var-
iants are also linked to antihypertensive drug response with relativelylarge effect size; such effects may arise as a result of an overlap be-
tween the homeostatic pathways mediating BP control and drug tar-
gets. Additionally, genomic variants known to be speciﬁcally
associated with antihypertensive drug response, published prior to
the time of analysis, will be evaluated.15 This will maximize the
power of our trial to detect genetic associations while avoiding the
limitations of a candidate gene approach. The association with metab-
olites will be exploratory, using a “metabolite-wide” association study
approach, while also revisiting metabolites that have previously been
deemed signiﬁcant in published metabolite-wide association studies
at the time of analysis.16,17
Sample size calculation
To identify the effect of ethnicity upon response to the various
treatment options trialed with 98% power, 200 patients from each of
the 3 ethnic groups, that is, 600 subjects per trial arm, will be required.
This assumes an SD for daytime systolic BP of 8 mmHg, use of a global
test of interaction at the 5% signiﬁcance level, and a single interaction
of 4 mm Hg with others of 0 mm Hg. Should the single interaction be
3 mmHg, the power is reduced to 81.3%. However, 4 mmHg is an ef-
fect size approximately 50% of that reported for some of the agents to
be used in this trial when studied among black and white participants
in the United States.18
To allow for a 10%dropout rate, the trialwill enroll 660 participants
per trial arm, with 220 subjects from each of the 3 ethnic groups. Re-
cruitment for each ethnic group will cease when 220 participants are
enrolled to ensure that equal numbers of patients are recruited. Sub-
group assessments are not powered, as these are exploratory
measures.
Statistical methods
The 2 crossover trials will be considered distinct entities for analyti-
cal purposes; the results will be interpreted separately on an intention-
to-treat basis. The primary end point—automated, ofﬁce SBP—will be
analyzed using a linear mixed-effects model. This end point will serve
as the dependent variable, participant ID the random effect, with
106 O. Mukhtar et al. / American Heart Journal 204 (2018) 102–108treatment factors, treatment period, ethnic group, and treatment by eth-
nic group the ﬁxed effects. The global test of interaction, at a 5% signiﬁ-
cance level, will be used to determine whether the treatment effect
varies with ethnicity. In the event of a signiﬁcant global test, the efﬁcacy
of individual agents/treatmentswill be estimatedwith nominal 95% CIs;
the assumptions of themodel will be assessed using graphical methods,
for example, aQ-Qplot andplots of residual versusﬁtted values. If any of
the assumptions are violated, the dependent variable may be trans-
formed to a normal distribution; if this fails to correct the distributional
assumptions, nonparametric methods will be used.
Analysis of secondary and tertiary outcomes will be dependent
upon the volume of data acquired; assessments of this (and the appro-
priate statistical methods) will be determined by the independent
chair of the Trial Steering Committee (TSC) (see below). A detailed sta-
tistical analysis plan will be produced before the database is locked
and/or before any interim analysis is performed.
Interim analysis and sample size reassessment
With limited prior data describing intraindividual SDs in SBP, the
multilevel nature of the trial design mandates an interim sample size
reestimation. Statistically robust and conﬁned to an analysis of SD in
BP, this will be undertaken for each trial arm (monotherapy and dual
therapy) after approximately 50 participants have completed at least
2 treatment periods. Given the likelihood that recruitment to the 2
arms will differ, it is anticipated that the sample size reestimations
are unlikely to occur simultaneously.
Only results of the sample size reestimation will be communicated
to investigators; the details of any treatment effects will not be made
available.
Organization and funding
The trial, sponsored byCambridgeUniversityHospitals NHS Founda-
tion Trust and theUniversity of Cambridge, is led by the Cambridge Clin-
ical Trials Unit at Cambridge University Hospitals NHS Foundation Trust.
Addenbrooke's Hospital, Cambridge, serves as the coordinating center,
whereas the Cambridge South (East of England) Research Ethics Com-
mittee provided a favorable ethical opinion for the protocol in October
2016.
A TSC consisting of experienced clinical investigators provides
overall supervision for the trial, ensuring that it is conducted in accor-
dance with the protocol and Good Clinical Practice. Convening at reg-
ular intervals and independently chaired (Prof Peter Sever), the
committee assumes overall responsibility for participant safety, con-
sideration of new information, and reviewing data, as speciﬁed in
the TSC charter.
Part of the wider AIM-HY consortium, the AIM-HY INFORM trial is
funded by the Medical Research Council and British Heart Foundation.
The sponsors and funding organizations have no role in the study de-
sign, study management, or data interpretation. The investigators (au-
thors) alone are responsible for these aspects of the study, as well as
any data analysis, the drafting and editing of manuscripts, and their
ﬁnal contents.
Current status
At present, 8 investigation centers are actively recruiting patients,
and it is anticipated that the trial will be completed by mid-late
2020; the results will be reported approximately 6-9 months later.
The ﬁrst patient was consented on 20 February 2017 and randomized
on 6March 2017; as of 15May 2018, 318 patients had been consented,
with 252 randomized. The study has been registeredwith theWeb site
ClinicalTrials.gov (NCT02847338).Commentary
Ethnicity inﬂuences BP status, at both an individual and population
level; epidemiological data from the United States demonstrate a
greater prevalence of hypertension among African Americans, along
with poorer BP control among this cohort of the population.19-22 How-
ever, data describing the prevalence of hypertension among the
United Kingdom's various ethnic groups are inconsistent. Some UK
studies describe a greater prevalence of hypertension, and signiﬁ-
cantly higher mean BP, in both Afro-Caribbean and South Asian popu-
lationswhen compared to the indigenouswhite population.23,24 Other
studies have shown signiﬁcant variations in BP data among subgroups
of the South Asian population, with some sections of this community
reportedly having lower BP readings than white adults; at various
times, these differences have been attributed to religion (eg, Muslim,
Sikh, Hindu), nation of origin (eg, India, Pakistan, Bangladesh), and
cultural grouping (eg, Gujarati, Punjabi).25-27 Furthermore, studies
which consider admixed populations are sparse despite the fact that
this cohort of the population is growing in size; more than 1 million
people in theUnited Kingdom identify as “mixed,”with 0.8% of the En-
glish and Welsh population describing themselves as being “white-
black Caribbean,” 0.6% “white-Asian,” 0.3% “white-black African,” and
0.5% “other mixed.”8
The pathophysiology of hypertension also appears to vary between
ethnic groups. In theUK SouthAsian population, elevated sympathetic ac-
tivity, arising from an increased prevalence of central obesity and insulin
resistance, is believed to be causally related to BP, whereas “low-renin”
hypertension is commonly described among black adults, with the
resulting salt andwater retention a signiﬁcant determinant of BP status.28-
32 In contrast, salt-sensitive hypertension is relatively infrequent in white
adults.31,32 Black patients are also reported to express variants of several
genes, most frequently a threonine to methionine substitution, T594 M,
affecting the renal tubular absorption of sodium and water.33 Phenotypi-
cally akin to Liddle syndrome, this pathophysiological mechanism is pri-
marily mediated via the renal tubular epithelial sodium channel.34
Treatment on thebasis of these observationshas resulted in theuse
of diuretics in hypertensive adults with low plasma renin activity and
antagonists of the renin-angiotensin axis (eg, angiotensin-converting
enzyme inhibitors [ACEi], angiotensin II receptor blockers [ARBs], or
β-blockers) in individuals with higher plasma renin activity.35-38 In
addition to this, the parallels to Liddle syndrome have led a number
of authors to advocate the use of amiloride among cohorts of black pa-
tients, both in the UK and elsewhere, whereas the elevated sympa-
thetic activity observed among South Asians has been used to justify
ACEi, ARB, and β-blocker use in this group.28,39
Although data relating to Asians in the North American literature are
limited—and where it is available, “Asian” frequently equates to “Far
Eastern” (Chinese, Japanese, etc)40,41—results from several large US
studies provide some evidence of ethnic variation in response to antihy-
pertensive drugs.34,42-47 In broad terms, greater falls in BP are achieved
with thiazide/thiazide-like diuretics in black subjects with hypertension
when compared to their white peers; conversely, ACEi are less effective
in this cohort. In the Antihypertensive and Lipid-Lowering Treatment to
PreventHeart Attack Trial, patients on chlorthalidone achieved better BP
control than those receiving lisinopril or amlodipine. Those using
lisinopril had a greater risk for stroke (risk ratio [RR]: 1.40, 95% CI:
1.17-1.68), combined cardiovascular disease (RR: 1.19, 95% CI: 1.09-
1.30), and heart failure (RR: 1.30, 95% CI: 1.10-1.54) compared with
those receiving chlorthalidone, treatment differences which were far
more pronounced in African Americans when compared with whites.42
Furthermore, the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial researchers reported a higher risk of stroke
in African American hypertensive patients treated with lisinopril as op-
posed to amlodipine (RR: 1.51; 95% CI: 1.22-1.86), an association which
was not observed in non–African Americans (RR: 1.07; 95% CI: 0.89-
107O. Mukhtar et al. / American Heart Journal 204 (2018) 102–1081.28).42 Subsequentmeta-analyses reiterate theseﬁndings, demonstrat-
ing no evident beneﬁt from ACEi in achieving diastolic blood pressure
(DBP) goals for African American hypertensive patients.48,49 Conversely,
ACEi may offer substantial beneﬁts for African Americans with hyper-
tensive renal disease; in the African American Study of Kidney Disease
and Hypertension, ramipril slowed renal disease progression in African
Americans irrespective of whether proteinuria was present, more so
than amlodipine or metoprolol.50 However, demographic differences
with the United Kingdom (eg, a large South Asian population, popula-
tion “admixture,” ﬁrst/second-generation immigrants as opposed to a
population resident for 2-3 centuries), along with variations in vascular
risk, diet, and weight, restrict the utility of US data.
The evidence for differential responses to antihypertensive drugs on
the basis of ethnicity in the United Kingdom is more limited, with an
analysis from203African, 132 SouthAsian, and 4,368white participants
in the UK arm of the Anglo-Scandinavian Cardiac Outcomes Trial per-
haps themost robust source of data.51 This sought to determinewhether
there were ethnic variations in response to monotherapy using β-
blockers (atenolol) or calcium channel blockers (amlodipine) and then
to add-on therapy with a thiazide diuretic (bendroﬂumethiazide) or
ACEi (perindopril). The degree of BP reduction achieved in black pa-
tients receiving atenolol monotherapy was signiﬁcantly lower when
compared to white patients; South Asian patients achieved an interme-
diate treatment effect. Amlodipine monotherapy resulted in similar BP-
lowering effects across all 3 ethnic groups, as did the addition of
bendroﬂumethiazide to atenolol. However, the addition of perindopril
to amlodipine resulted in statistically signiﬁcant BP differences; white
patients achieved a further 1.7–mm Hg fall in SBP (95% CI: −2.8 to
−0.7 mm Hg), black patients exhibited a diminished response (SBP
change:−0.8 mm Hg; 95% CI:−2.5 to +4.2 mm Hg), whereas South
Asians demonstrated a greater response (SBP change:−6.2 mm Hg;
95% CI−10.2 to−2.2 mm Hg).51
The AIM-HY INFORM trial aims to optimize ﬁrst- and second-line
antihypertensive therapies for the multiethnic population of the
United Kingdom. In doing so, it will reﬁne the “black versuswhite” ap-
proach embodied in the current NICE guideline and further codify the
treatment of hypertension. The systematic and robust trial data pro-
duced will also compare the value of SDE against genetically deﬁned
ancestry andmetabolomics, informing future studies in low- andmid-
dle-income countries, where the utilization of existing generic drugs
in a resource-efﬁcient manner is imperative.Acknowledgements
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